(3,7-diazabicyclo[3.3.1]non-3-yl)-furan-2-yl-methanone trifluoroacetate | 1025007-66-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3,7-diazabicyclo[3.3.1]non-3-yl)-furan-2-yl-methanone trifluoroacetate
• 英文别名: 3,7-Diazabicyclo[3.3.1]nonan-3-yl(furan-2-yl)methanone;2,2,2-trifluoroacetic acid
• CAS: 1025007-66-2
• 化学式: C₂HF₃O₂*C₁₂H₁₆N₂O₂
• 分子量: 334.295
• InChiKey: JIDIEBRDKUYZNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.59
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  82.8
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (3,7-diazabicyclo[3.3.1]non-3-yl)-furan-2-yl-methanone trifluoroacetate 、 三氟乙酸 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 (3,7-diazabicyclo[3.3.1]non-3-yl)-furan-2-yl-methanone trifluoroacetate
  参考文献：
  名称：

  WO2008/57938

  摘要：

  公开号：

文献信息

• NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES
  申请人：Mazurov Anatoly

  公开号：US20100081683A1

  公开（公告）日：2010-04-01

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteoraryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the a4β2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).

  本文公开了化合物、包括这些化合物的制药组合物的制备方法和使用方法。这些化合物是酰胺化合物，可以从某些杂环羧酸和某些二氮杂双环烷制备而成。这些化合物表现出选择性，并与中枢神经系统(CNS)的a4β2亚型的神经尼古丁受体结合亲和力高。这些化合物和组合物可用于治疗和/或预防各种疾病或疾病，特别是CNS疾病。这些化合物可以：（i）改变患者大脑尼古丁胆碱能受体的数量，（ii）表现出神经保护作用，（iii）当以有效量使用时，不会产生明显的不良副作用（例如显著增加血压和心率、对胃肠道产生显著负面影响以及对骨骼肌产生显著影响等副作用）。
• Nicotinic Acetylcholine Receptor Sub-Type Selective Amides of Diazabicycloalkanes
  申请人：Mazurov Anatoly

  公开号：US20120289572A1

  公开（公告）日：2012-11-15

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).

  本文公开了一种化合物、包括该化合物的制药组合物以及其制备和使用方法。该化合物是酰胺化合物，可以从某些杂环羧酸和某些二氮杂双环烷制备而成。该化合物在中枢神经系统（CNS）中表现出对α4β2亚型的神经尼古丁受体的选择性和高亲和力。该化合物和组合物可用于治疗和/或预防各种疾病或障碍，尤其是CNS障碍。该化合物可以：（i）改变患者大脑尼古丁胆碱受体的数量，（ii）表现出神经保护作用，以及（iii）在有效剂量下，不会产生明显的不良副作用（例如，明显增加血压和心率、对胃肠道产生明显负面影响和对骨骼肌产生明显影响等副作用）。
• SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES
  申请人：Mazurov Anatoly

  公开号：US20100173932A1

  公开（公告）日：2010-07-08

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).

  本文披露了化合物、包括该化合物的制药组合物以及其制备和使用方法。这些化合物是酰胺化合物，可以从特定的杂环羧酸和特定的二氮杂双环烷制备而成。这些化合物在中枢神经系统（CNS）中表现出对α4β2亚型的神经元尼古丁受体的选择性和高亲和力。这些化合物和组合物可以用于治疗和/或预防各种疾病或紊乱，特别是CNS疾病。这些化合物可以：（i）改变患者大脑尼古丁胆碱受体的数量，（ii）表现出神经保护效果，以及（iii）在有效剂量下，不会产生明显的不良副作用（例如明显增加血压和心率、对胃肠道产生明显负面影响以及对骨骼肌产生明显影响等副作用）。
• Amides of diazabicycloalkanes selective for nicotinic acetylcholine receptor sub-types
  申请人：Targacept, Inc.

  公开号：EP2284171A1

  公开（公告）日：2011-02-16

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroraryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the a4ss2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). Formula I: wherein n has the value of 0 or 1, and Cy is a heteroaryl group chosen from the group of 2-furanyl, 3-furanyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1,3,4-thiadiazol-2-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl and 4-pyridinyl.

  本发明公开了化合物、包括化合物的药物组合物及其制备和使用方法。这些化合物是酰胺类化合物，可由某些杂芳基羧酸和某些二氮杂双环烷烃制备。这些化合物对中枢神经系统（CNS）中的 a4ss2 亚型神经元烟碱受体具有选择性，并能与之高亲和力地结合。这些化合物和组合物可用于治疗和/或预防多种疾病，尤其是中枢神经系统疾病。这些化合物可以(i) 改变患者大脑中烟碱胆碱能受体的数量；(ii) 表现出神经保护作用；(iii) 以有效量使用时，不会产生明显的不良副作用（例如，血压和心率明显升高、对胃肠道产生明显负面影响以及对骨骼肌产生明显影响等副作用）。 式 I： 其中 n 的值为 0 或 1，且 1,2,4-恶二唑-5-基、2-噻唑基、4-噻唑基、5-噻唑基、3-异噻唑基、4-异噻唑基、5-异噻唑基、1,3,4-噻二唑-2-基、1,2,4-噻二唑-3-基、1,2,4-噻二唑-5-基和 4-吡啶基。
• NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES
  申请人：Targacept, Inc.

  公开号：EP2094703A1

  公开（公告）日：2009-09-02